Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Join | Sign in
Home>Resources>Webcasts>This Webcast
  Webcasts

Drug-Drug Interactions Involving non-CYP Phase I or Phase II Enzymes can we Predict?

Olivier Barberan, Director of Product Development, Aureus Pharma, speaking at ADMET Europe
Date Posted: Thursday, September 16, 2010
Access to this article and other content is for registered users.

Join the Technology Networks Community

  • Access to the latest scientific news, products and research through Technology Networks
  • Upload and share your posters on ePosters
  • View a library of 1,800+ scientific and medical posters
  • A library of 3,000+ scientific videos on LabTube


Sign In



Forgotten your details? Click Here
If you already have an account with Technology Networks, please use your existing login details. If you do not yet have an account please join here.

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Related Content

Aureus Pharma Announces Participation in EUR 118 Million Biointelligence R&D Programme
The programme is aimed to promote the use of Systemic Modelling and Simulation Tools In The Life Science Industry.
Tuesday, March 23, 2010
Aureus Pharma Extends its Knowledge Database Agreement with Sanofi-Aventis R&D
Aureus will provide new AurSCOPE® knowledge databases and continue to update existing databases for sanofi-aventis' R&D division.
Friday, November 06, 2009
Aureus Pharma to Participate in a European Consortium for Drug Cardiac Toxicity
Aureus’ contribution to the project will be to use its expertise in Ion Channel/hERG knowledge databases to predict the effects of drugs on the heart.
Friday, October 31, 2008
Aureus Pharma Licenses AurWEB to Origenis
AurWEB is designed to allow access to all of Aureus’ knowledge databases, which include AurSCOPE GPCR, Ion Channel, Kinase, ADME/Drug-Drug interactions and hERG.
Thursday, September 07, 2006
Aureus Licenses AurSCOPE ADME/DDI and hERG Knowledge Databases to Siena
Aureus’ ADME/DDI and hERG knowledge databases contain data which can help assess the safety of a potential pharmaceutical candidate.
Thursday, June 08, 2006
Scientific News
Artificial Pancreas Controls Diabetes
Scientists are reporting the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar, or glucose, level and can automatically release insulin as needed.
Elastic Gel to Heal Wounds
A team of bioengineers at Brigham and Women’s Hospital has developed a new protein-based gel that, when exposed to light, mimics many of the properties of elastic tissue, such as skin and blood vessels.
Researchers Develop a New Means of Killing Harmful Bacteria
Engineered particles are capable of producing toxins that are deadly to targeted bacteria.
Smart Insulin Patch Could Replace Painful Injections for Diabetes
A joint effort between diabetes doctors and biomedical engineers could revolutionize how people with diabetes keep their blood sugar levels in check.
Algal Blooms Pose Health Risks Downstream
A new study has found that toxic algal blooms in reservoirs on the Klamath River can create unsafe water conditions far downstream on lower parts of the river in northern California.
New Type of Drug Can Target All Disease-causing Proteins
Current drugs block the actions of only about a quarter of known disease-causing proteins, but Yale University researchers have developed a technology capable of not just inhibiting, but destroying every protein it targets.
The Perfect Partnership: Research & Industry; Software & Instrumentation. It really starts to come together at ASMS 2015
Collaboration and knowledge-sharing were evident everywhere: on the bus, in the hallways and in the bars. This article aims to capture this theme and share with you some of the fruits of this coming together of science and industry.
Designing New Pain Relief Drugs
Researchers have identified the molecular interactions that allow capsaicin to activate the body’s primary receptor for sensing heat and pain, paving the way for the design of more selective and effective drugs to relieve pain.
How C. difficile Toxins enter Cells
Clostridium difficile is a dangerous intestinal bacterium that can cause severe diarrhoea and life-threatening intestinal infections after long-term treatment with antibiotics.
Bacteria Cooperate to Repair Damaged Siblings
New research unearths the unique ability of a certain type of soil borne bacteria to repair nearby damaged cells.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters